Last reviewed · How we verify

NCT04379180

Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN

Status unknown Last updated 7 May 2020
What this trial tests

trial testing Bosentan Tablets in Persistent Pulmonary Hypertension of the Newborn in 500 participants. Status unknown.

Timeline
26 April 2020
Primary endpoint
26 February 2023
30 May 2023

Quick facts

Lead sponsorShandong University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date26 April 2020
Primary completion26 February 2023
Estimated completion30 May 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shandong University

Who can join

Under 28 Days, any sex, with Persistent Pulmonary Hypertension of the Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of bosentan, sildenafil and tadalafil in neonates with persistent pulmonary hypertension (PPHN) depends mostly on the empirical experience of pediatricians. Moreover, the recommended dose of those three drugs in treating PPHN remains controversial. Therefore, our aim is to study the pharmacokinetics and pharmacodynamics of bosentan, sildenafil and tadalafil in neonates of PPHN then dose a tailor-made therapeutic regimen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Persistent Pulmonary Hypertension of the Newborn

Currently open trials in the same condition.

Other Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04379180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing